Neuromod Devices
Monday, 30 September 2019
ByrneWallace advised Neuromod Devices, a medical technology company in connection with an €8 million fundraising, comprising of both equity investment and venture-debt. Neuromod will use this funding to increase their manufacturing capacity in Europe and progress its regulatory strategy for the US. This financing round was led by existing investors Fountain Healthcare Partners and Moffett Investment Holdings, with venture-debt being provided by Kreos Capital and Silicon Valley Bank.
Founded in 2010, Neuromod specialises in non-invasive neuromodulation technologies. The company recently opened a centre of excellence specialising in neuromodulation and tinnitus in Dublin, offering tinnitus assessments and treatment with its Lenire tinnitus treatment system.
The ByrneWallace team who advised on this transaction included Catherine Dowling (Partner, Corporate & Life Science), Colin Sainsbury (Partner, Head of Life Sciences), Mark Kavanagh (Partner and Head of Banking), Triona Ryan (Senior Associate, Banking), Catherine Finn (Solicitor, Corporate & Life Sciences) and Genevieve Gallagher (Solicitor, Banking).
For more information on this transaction and to view Neuromod’s press release click here.
